Clinical trials
Observational Prostatic Neoplasms trials in France
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
90 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2002 | 1 |
| 2003 | 1 |
| 2006 | 1 |
| 2007 | 1 |
| 2009 | 1 |
| 2010 | 4 |
| 2011 | 4 |
| 2013 | 3 |
| 2014 | 2 |
| 2015 | 6 |
| 2016 | 7 |
| 2017 | 5 |
| 2018 | 6 |
| 2019 | 7 |
| 2020 | 9 |
| 2021 | 6 |
| 2022 | 6 |
| 2023 | 5 |
| 2024 | 7 |
| 2025 | 4 |
| 2026 | 3 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 57 |
| Unknown status | 14 |
| Recruiting | 13 |
| Terminated | 3 |
| Active, not recruiting | 2 |
| Withdrawn | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Hospices Civils de Lyon | 10 |
| Assistance Publique - Hôpitaux de Paris | 7 |
| University Hospital, Brest | 5 |
| Institut Bergonié | 4 |
| Bayer | 3 |
| Central Hospital, Nancy, France | 3 |
| Centre Hospitalier Universitaire de Nīmes | 3 |
| Ferring Pharmaceuticals | 3 |
| Institut Paoli-Calmettes | 3 |
| Ipsen | 3 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Prostatic Neoplasms | 90 |
| Breast Neoplasms | 11 |
| Neoplasms | 10 |
| Kidney Neoplasms | 8 |
| Lung Neoplasms | 7 |
| Ovarian Neoplasms | 5 |
| Urinary Bladder Neoplasms | 5 |
| Colonic Neoplasms | 4 |
| Colorectal Neoplasms | 4 |
| Neoplasm Metastasis | 3 |
Trials
Showing 1 to 25 of 90. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.